3.15 The impact of smoking on treatment of disease

Last updated: Jan 2021
Suggested citation: Just, J, Winnall, W, Hurley, S, Greenhalgh, EM & Winstanley, MH. 3.15 The impact of smoking on treatment of disease. In Greenhalgh, EM, Scollo, MM and Winstanley, MH [editors]. Tobacco in Australia: Facts and issues. Melbourne: Cancer Council Victoria; 2021. Available from  http://www.tobaccoinaustralia.org.au/3-15-smoking-and-complications-in-medical-treatmen


3.15.1 Surgery

Smoking increases the risk of intraoperative (anaesthetic) and postoperative complications.1 Smokers’ higher prevalence of chronic diseases, impaired pulmonary reserve and altered immune responses are thought to contribute to these complications. Poorer surgical outcomes result.2

In 2020, the World Health Organization released an updated review of tobacco and post-surgical outcomes that suggested that smokers who quit around 4 weeks prior to surgery have a lower risk of operative complications. However, the ideal cessation time varies according to the specific complication.3 Anaesthesia

The effectiveness of a number of commonly used anaesthetic drugs is reduced in smokers. Higher doses are therefore required. These drugs include opioids,4 neuromuscular blocking agents and some of the volatile agents that are administered by inhalation (via a mask or endotracheal tube).5 The polycyclic aromatic hydrocarbons in cigarette smoke induce the liver enzymes that metabolise anaesthetics, at least partly accounting for these effects. Smoking does, however, decrease postoperative nausea and vomiting, possibly because of the increased metabolism of volatile anaesthetics.5

Smoking cessation before surgery can reduce the requirement for perioperative opioids, demonstrated in a study of people having laparoscopic distal gastrectomy with gastroduodenostomy (removal of part of the stomach). People who quit for longer than one month prior to surgery required less perioperative opioids than those who quit for less than one month prior to surgery.6

Smoking also increases the risk of intraoperative respiratory complications, including bronchospasm, aspiration, hypoventilation and hypoxaemia.7-9 A higher concentration of remifentanil may be needed to prevent cough during emergence from anaesthesia for smokers compared to non-smokers.10

The Australian and New Zealand College of Anaesthetists recommends that patients who smoke be encouraged to quit at any time before surgery.11  Research suggests that recent quitters are no worse off than continuing smokers in terms of pulmonary complications. (see Section, 13 Postoperative complications

It is well-established that smoking results in a significantly increased risk of many postoperative complications. These complications include a higher risk of general morbidity, wound complications, lung complications, infections, neurological complications and an increased risk of intensive care unit (ICU) admission post-surgery.14

-Wound and surgical site complications

Smoking delays wound healing after surgery.1 Complications for which smokers have a greater risk include: wound infection;15 dehiscence (bursting of sutures);16 erosions (destruction of tissue surfaces) and necrosis (death of most of the cells of a piece of tissue or an organ);17 hernia (protuberance of organs through cavity walls); poor healing of broken bones; poor healing of fistulae (abnormal openings from body organs to the surface of the skin) and incomplete wound healing in people with critical limb ischemia undergoing endovascular interventions.18-21  

Smoking has an impact on wound healing via several different pathophysiological mechanisms, including:22, 23

  • Reduced blood flow to, and oxygenation of, peripheral tissues
  • Impaired inflammatory processes that are part of normal healing
  • Impaired proliferation of fibroblasts and collagen production
  • Impaired immune function, which may increase the risk of wound infection3

Such wound complications are particularly problematic after plastic and reconstructive surgery, bariatric surgery, bowel surgery, hernia repair surgery, dental surgery (see Section 3.11.4), microsurgery, and organ transplantation.11, 17, 24-26

-Complications following cardiac surgery and cardiac procedures  

A meta-analysis found smokers undergoing cardiac surgery were at increased risk of pulmonary complications and pneumonia following surgery, but had a reduced risk of kidney complications, compared to ex-smokers.27

A systematic review and meta-analysis of patients undergoing repair of an aneurysm (enlargement or ballooning of an artery due to a weakness in the artery wall) found that smoking was protective again endovascular leaks post-surgery.28 The paper proposed possible explanations for this; smokers are more likely to have extensive atherosclerosis, potentially protecting against leakage, and smoking increases aggregation of platelets, increasing clot formation, so leakage becomes less likely.

Smokers had an almost two-fold increased chance of poor outcomes (death, myocardial infarction, or stroke) within five years after coronary revascularisation, whereas former smokers were not at increased risk.29 Smokers also have an increased risk of death after carotid endarterectomy (plaque removal procedure to reduce the risk of stroke).30

-Complications following orthopaedic surgery

Smokers have an increased risk of complications following several types of orthopaedic surgery (see Section 3.13.2), including shoulder surgery, and hip and knee arthroplasty (replacement).31-37 Smoking is an independent risk factor for complications after shoulder surgery (open rotator cuff repair), including 4.6-fold higher chance of a thromboembolic event (blood clotting, such as deep vein thrombosis), 6.4-fold higher chance of pulmonary embolism (blood clot in the lung),38 2.5-fold higher chance of return to the operating room, 1.6-fold higher chance of readmission and 4.7-fold higher chance of sepsis or septic shock.39

A meta-analysis found smokers had a higher risk of loosening of prostheses (artificial body parts inserted during surgery), deep infection, and the need for revision following total hip arthroplasty (hip replacement).31 Another study found an increased risk of periprosthetic joint infection (infection around the artificial body part) in smokers undergoing total hip or knee arthroplasty.33 A meta-analysis of 10 studies from 2020 found that smokers were at 1.5-fold increased risk of prosthetic joint infection requiring surgery after total hip replacement.40

People who smoke had almost four-fold greater odds than non-smokers of needing re-operation after a common spinal procedure called posterior cervical decompression,41 and a 2.5-fold increased chance after lumbar discectomy.42 Smoking was a risk factor for longer stay in intensive care after surgery for spine trauma.43 Smokers also had increased pain and disability one year after a spinal surgery called lumbar tubular microdecompression.44

After accounting for the effects of other risk factors, smoking was an independent risk factor for major complications after hand surgery. A large cohort study of over 48,000 people having hand surgery showed that smokers were at higher risk of infections and wound healing complications.45 Smokers have a higher risk of adverse events within 30 days of surgical treatment for a broken wrist. Smokers had a 1.75-fold higher risk of any adverse event, 1.73-fold higher risk of infection, 2.1-fold increased risk of reoperation and 1.8-fold increased risk of readmission compared to non-smokers.46 Smoking was also associated with a small increase in the chance of needing readmission for complications after craniotomy surgery47 and repair of small umbilical and epigastric hernias.48

A study also found smoking increases the risk of venous thromboembolism (VTE) (blood clots that form in veins) following anterior cruciate ligament (ACL) reconstruction surgery.49 Another study found smokers had higher rates of wound infection, VTE and subsequent ACL reconstruction compared to non-smokers.50

-Complications following plastic and reconstructive surgery

Following breast reconstruction, smoking has been associated with a doubling of the risk of complications (such as mastectomy flap necrosis and infection) and a five-fold increase in the risk of implant failure.51 Such poor surgical outcomes have led to a call for caution when undertaking breast reconstruction in smokers.52 Similarly, impaired wound healing and wound infection in smokers undergoing breast reduction surgery53, 54 have led to a suggestion that pre-operative smoking cessation be an essential eligibility criterion for this surgery.54 In another study of patients undergoing reduction mammaplasty (breast reduction), smoking was associated with an increased risk of wound complications including dehiscence.55, 56

-Complications following transplant surgery

Smokers undergoing organ transplantation have poorer outcomes,57 including increased mortality after liver transplantation,24 increased kidney transplant rejection,58 and poorer survival after heart transplantation if either the donor was, or the recipient is, a smoker.59-63

Unsurprisingly, solid organ transplant recipients who smoke post-transplant are at higher risk of newly diagnosed cardiovascular disease, cancer and overall shorter survival time, and  mortality.61

The poorer organ transplantation outcomes in smokers, combined with the high demand for donated organs, have led to suggestions that smokers be given lower priority for organ transplants and debate about the ethics of such a policy.64-66

Where the transplant donor was a smoker, there is also an increased risk of poor outcomes. People with a history of smoking who donated a kidney during live kidney donation have 3.3-fold higher chance of developing chronic kidney disease after the surgery.67 A donor history of smoking is associated with an increased risk of clotting after liver transplant, and increased risk of graft rejection and mortality in the recipient.68


-Complications following other types of surgery

Smoking increases the risk of complications following other types of surgery including: a higher failure rate for oral mucosa graft urethroplasty (repair of the urethra with a graft from the lining of the mouth);69 worse hearing and the need for repeat operations after ear surgery;70 increased complications post appendicectomy71 and hernia repair;26, 72 and increased risk of complications following bariatric surgery including prolonged intubation (insertion of a tube through the mouth to support artificial breathing) and organ space infection (a type of surgical site infection).73 Another study suggested that in patients undergoing sleeve gastrectomy (surgery involving removal of part of the stomach) for weight management, smokers had an increased risk of morbidity and mortality compared to non-smokers (of note, ‘smokers were those who had smoked at least one cigarette in the year prior to surgery, ‘non-smokers’ were those that had not).74 A systematic review of the association of smoking with post-operative complications after bariatric surgery found that smoking was an independent risk factor for increased 30-day mortality and major and pulmonary complications. Smoking was also associated with long-term complications such as ulceration and bone fracture but had minimal effect on weight loss following surgery.75

Smokers having a lobectomy for lung cancer had a higher risk of post-operative complications. In a study of over 5,000 people, current smokers had a 1.5-fold higher chance of suffering a pulmonary complication and 1.7 higher odds of suffering multiple complications than non-smokers or recent quitters (2 weeks to 3 months prior to surgery).76 Impact of smoking cessation

A systematic review published in 2012 explored the relationship between short-term preoperative smoking cessation and postoperative complications and concluded that at least four weeks of abstinence from smoking reduces respiratory complications, and abstinence of at least three to four weeks reduces wound-healing complications. Short-term (less than four weeks) smoking cessation did not appear to increase or reduce the risk of postoperative respiratory complications.77

A 2014 Cochrane Review examined interventions for smoking cessation preoperatively, and the impact of this on postoperative complications.78 Thirteen RCTs, with over 2000 participants, were included in the review. Intensive behavioural interventions (face-to-face counselling delivered over multiple sessions) were found to reduce the risk of any postoperative complications, and wound complications specifically. However, brief interventions did not have an impact. The authors concluded that although the ideal cessation time is not entirely clear, evidence suggests that interventions that commence at least four weeks before surgery, and that involve weekly counselling and pharmacotherapy, can reduce the risk of complications.

A study of over 6000 patients undergoing coronary artery bypass graft (CABG) surgery also found that cessation of at least four weeks’ reduced the risk of lung complications following surgery, including lung infection and reintubation.79 A further study demonstrated that smoking abstinence following CABG reduced the 5 year mortality rate by 35%.80

The Australian and New Zealand College of Anaesthetists recommend that, based on the current available evidence, anaesthetists and surgeons should not be dissuaded from advising patients to quit at any time before surgery.11

3.15.2 Drug interactions

Smoking alters the effects of a number of medications (see also Section on interactions with anaesthetics). Doctors and other health professionals need to be aware of these interactions when medications are prescribed and also when patients quit smoking, as drug dosages may need to be adjusted.81

Drug interactions fall into two categories: (i) pharmacokinetic interactions, which occur when cigarette smoke alters a drug’s metabolism; or (ii) pharmacodynamic interactions, which occur when the physiological effects of cigarette smoke modify the physiological effects of the drug.82, 83

Pharmacokinetic interactions include increased metabolism of caffeine, heparin, warfarin, theophylline, beta-blockers (such as propranolol), a number of antipsychotic drugs (such as clozapine, chlorpromazine and olanzapine) and benzodiazepines.84-86 A meta-analysis of the interaction between smoking and warfarin, for example, found that smoking increased warfarin dosage requirements by about 12%.87 Smokers with lung cancer had increased clearance of erlotinib (a non-chemotherapy) and irinotecan (a chemotherapy), which may reduce their effectiveness in treating the lung cancer.88 Smokers with chronic obstructive pulmonary disease (COPD) gained less benefit from inhaled corticosteroids than did non-smokers; they had poorer lung function and increased exacerbations of disease.89

Although it is difficult to know which of the estimated 7,000 compounds in cigarette smoke cause these interactions,90 the polycyclic aromatic hydrocarbons are suspected. These hydrocarbons induce liver enzymes (see Chapter 3, Section and thereby hasten the clearance of any drug (or substance) whose metabolism requires the enzymes.82, 83 Conversely, upon smoking cessation, dosages of these medications may need adjustment, as clearance will slow. For example, upon stopping smoking, smokers may need to reduce caffeine consumption.84

The pharmacokinetic interaction between tobacco smoke and the antiplatelet medication clopidogrel has been described as a ‘smoking paradox’ as there is some evidence to suggest that smokers have higher clinical responsiveness to clopidogrel than non-smokers.84 A meta-analysis of over 70,000 patients with established cardiovascular disease found that smokers taking clopidogrel had a 25% lower risk of cardiovascular events compared to an 8% reduced risk in non-smokers.91  Another study suggested that doubling the dose of clopidogrel in smokers was effective in reducing the risk of cardiovascular events, without an increase in the risk of bleeding.92 Dosages of clopidogrel and other antiplatelet medications (such as prasugrel) may need to be adjusted upon stopping smoking.93

A meta-analysis showed that smokers had significantly lower blood levels of the antipsychotic drug clozapine. The authors recommended a 30% reductions of clozapine dose for those who quit smoking94 (see also Section 9A.3).

Pharmacodynamic interactions include: reduced response to corticosteroids in smokers who are asthmatic,95, 96 decreased effectiveness of benzodiazepines (a common sleeping medication) (possibly due to the stimulant effects of nicotine), slowed absorption of sub-cutaneous insulin among diabetics (possibly due to reduced blood flow to the skin, mediated by nicotine), and an increased risk of cardiovascular adverse effects in women taking oral contraceptives.82, 83

In the above examples, smoking modifies the effects of particular drugs. It has also been hypothesised that bronchodilator drugs (mainly beta-2-agonists), prescribed for people with chronic obstructive pulmonary disease (COPD), may worsen the effects of cigarette smoke. The theory is that bronchodilation improves smoke inhalation, and may increase the deposition of cigarette smoke on the lungs, thereby increasing cardiovascular disease morbidity and mortality. This hypothesis is yet to be tested.97

3.15.3 Cardiovascular disease

As detailed in Section 3.1, smoking causes cardiovascular disease, and generally, if a person continues to smoke after developing cardiovascular disease their prognosis is worse than if they had quit.

For example, a study of more than 18,000 patients who were receiving a statin drug for coronary disease found that over a five-year period those who continued to smoke had about a 50% higher chance of a major cardiovascular event (heart attack, stroke, cardiac arrest or death) than patients who quit.98  However, a more recent meta-analysis found that the risk of major cardiovascular events in people using statins was similar for smokers and non-smokers.99

Poorer treatment outcomes have been reported for people who continue to smoke after coronary artery bypass grafting100 or a diagnosis of heart failure,101 compared with people who quit.

A 2019 meta-analysis involving over 120,000 patients undergoing either percutaneous coronary intervention (i.e. placement of a stent, a small device to open up an artery) or CABG found that smokers had a higher risk of all-cause mortality compared to non-smokers.102 However, there was no statistically significant difference in the rate of heart attacks, all cardiovascular events or cardiovascular deaths . The increased risk of all-cause mortality was also true of ex-smokers, compared to non-smokers.

3.15.4 Cancer

As detailed in Section 3.5, smoking causes numerous cancers.

The 2014 Surgeon General’s report was the first in its series to review the associations between cigarette smoking and health outcomes in cancer patients and survivors. It concluded that smoking causes adverse health outcomes in people with cancer, while cessation improves their prognosis. Smoking increases all-cause mortality and cancer-specific mortality in cancer patients and survivors, and increases the risk of second primary cancers that are caused by cigarette smoking, including lung cancer. Smoking may increase the risk of recurrence, result in a poorer response to treatment, and increase treatment-related toxicity.103

A 2018 review published by the World Health Organization identified some of the mechanisms by which smoking affects outcomes of cancer treatment.104 These mechanisms include increased cancer cell proliferation, migration and metastasis (development of secondary cancers), acceleration of systemic clearance of cancer therapies (potentially impacting efficacy of cancer treatment), increased complications associated with treatment, and an increased risk of co-morbidities related to tobacco.

The review also reinforced findings from the Surgeon General’s report, regarding the impact of smoking on cancer outcomes, including increased risk of all-cause mortality, cancer-specific mortality, recurrence, and reduced quality of life. Specifically, this included studies of patients with lung cancer, head and neck cancers, bladder cancer and breast cancer.104

A 2018 meta-analysis of patients with colorectal cancer found that current and former smokers had lower overall survival compared with never smokers. In the same study, smoking cessation, compared to current smoking, was linked with an improvement in overall and colorectal cancer-specific survival.105 Smoking has also been identified as a risk factor for superficial surgical site resections in patients undergoing rectal cancer resection.106

More severe pain has been associated with smoking in patients with cancer,107 and specifically for lung cancer108 and head and neck cancer.109 This may be because of the decreased effectiveness of opioids (due to increased drug metabolism caused by cigarette smoke components) described in Chapter 3, Section, and failure to increase the dose in response.

Smokers with bladder cancer who had surgery to remove their bladder had poorer outcomes than non-smokers. They had an increased risk of overall mortality, cancer-specific mortality and recurrence of bladder cancer.110

A meta-analysis showed that smoking was associated with increased risk of complications, such as skin reactions and reduced pulmonary function, for people with breast cancer having adjuvant radiotherapy (radiotherapy after initial treatment, such as surgery).111

Stem cell transplantation can be an effective treatment for some blood cancers. In a cohort study, smoking was found to be an independent risk factor for mortality within five years after stem cell transplantation.112

A 2019 meta-analysis did not find any difference in response to immunotherapy (for treatment of advanced solid organ cancers) between ever smokers and never smokers.113 However, since this report, numerous studies and meta-analyses have found that immunotherapy using PD-1 or PD-L1 inhibitors (a major class of immunotherapies) had greater efficacy for smokers than non-smokers. Never smokers with non-small cell lung cancer (NSCLC) treated with pembrolizumab (a PD-1 inhibitor) had higher risk of disease progression and death compared to smokers.114 Smokers with metastatic urothelial carcinoma treated with pembrolizumab also had a lower risk of disease progression and mortality compared to non-smokers.115 A meta-analysis of high quality trials testing any PD-1/PD-L1 inhibitor on any cancer found similar results. Non-smokers had no increase in survival with the immunotherapies above the benefit of chemotherapy, however smokers benefitted more from immunotherapy than from chemotherapy.116 A similar meta-analysis also found that current or former smokers had an increase in progression-free survival and overall survival with PD-1/PD-L1 immunotherapy compared to chemotherapy, irrespective of cancer type.117 It should be noted that a greater benefit of PD-1/PD-L1 immunotherapy over chemotherapy for smokers does not necessarily mean that smokers have increased survival from these cancers overall, rather that PD-1/PD-L1 immunotherapy is a more effective treatment for smokers than chemotherapy in specific circumstances. Smoking causes an increased risk of mortality for people with cancer and an increased risk in a second primary cancer.103

Smoking cessation improves outcomes in cancer patients. Cessation is associated with  an improved quality of life (in patients with lung or head and neck cancers), reduced risk of cancer-specific mortality (in patients with breast cancer) and improvement in survival (for patients with lung cancer, head and neck, colorectal and bladder cancer).118 Patients who stop smoking also experience reduced treatment-related toxicity.118, 119

A 2019 retrospective study on patients with primary lung cancer who had undergone lung resection, found that smoking cessation reduced the risk of lung complications following surgery and mortality rate at 90 days. The longer the period of cessation, the lower the risk of lung complications.120

For an overview of smoking cessation interventions for people with cancer, see Section 7.12.4.

3.15.5 Treatment of infertility including assisted reproduction

See Section 3.6.3.

3.15.6 Other conditions

A meta-analysis published in 2011 found that in patients receiving long-term haemodialysis (use of an artificial kidney machine to clean the blood) or peritoneal dialysis (an alternative to haemodialysis, uses the lining of the abdomen to clean the blood), smoking increased the death rate (all-cause mortality) by 65%.134

A 2019 meta-analysis and systematic review found that burns patients who smoke have higher rates of complications compared to non-smokers, including an increased risk of intubation (insertion of a tube through the mouth to support artificial breathing) and skin infections.135

For the effects of smoking on contraception, see Section 3.6.4.

Relevant news and research

For recent news items and research on this topic, click  here. ( Last updated March 2024)



1. World Health Organization. Smoking greatly increases risk of complications after surgery - WHO. World Health Organization,  2020. Available from: https://www.who.int/news-room/detail/20-01-2020-smoking-greatly-increases-risk-of-complications-after-surgery

2. US Department of Health and Human Services. The health consequences of smoking: a report of the Surgeon General. Atlanta, Georgia: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. Available from: http://www.cdc.gov/tobacco/data_statistics/sgr/index.htm.

3. Yoong S, Tursan d'Espaignet E, Wiggers J, St Claire S, Mellin-Olsen J, et al. WHO tobacco knowledge summaries: tobacco and postsurgical outcomes Geneva: World Health Organisation 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/330485/9789240000360-eng.pdf

4. Woodside JJ. Female smokers have increased postoperative narcotic requirements. Journal of Addictive Diseases, 2000; 19(4):1–10. Available from: https://www.tandfonline.com/doi/abs/10.1300/J069v19n04_01

5. Sweeney BP and Grayling M. Smoking and anaesthesia: the pharmacological implications. Anaesthesia, 2009; 64(2):179-86. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19143696

6. Kim CS, Sim JH, Kim Y, Choi SS, Kim DH, et al. Association between postoperative opioid requirements and the duration of smoking cessation in male smokers after laparoscopic distal gastrectomy with gastroduodenostomy. Pain Research and Management, 2021; 2021:1541748. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33574973

7. Moller AM, Maaloe R, and Pedersen T. Postoperative intensive care admittance: the role of tobacco smoking. Acta Anaesthesiologica Scandinavica, 2001; 45(3):345-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11207472

8. Schwilk B, Bothner U, Schraag S, and Georgieff M. Perioperative respiratory events in smokers and nonsmokers undergoing general anaesthesia. Acta Anaesthesiologica Scandinavica, 1997; 41(3):348-55. Available from: https://www.ncbi.nlm.nih.gov/pubmed/9113178

9. Al-Sarraf N, Thalib L, Hughes A, Tolan M, Young V, et al. Effect of smoking on short-term outcome of patients undergoing coronary artery bypass surgery. Annals of Thoracic Surgery, 2008; 86(2):517-23. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18640326

10. Kim HY, Choi JB, Lee EA, Kwon SH, Kim JE, et al. Effects of smoking on the optimal effect-site concentration of remifentanil required for preventing cough during anesthetic emergence in male patients undergoing laparoscopic or robotic cholecystectomy. Medicine, 2021; 100(13):e25288. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33787614

11. Australian and New Zealand College of Anaesthetists (ANZCA). Guidelines on smoking as related to the perioperative period. 2014. Available from: https://www.anzca.edu.au/getattachment/5deb6800-e8f9-453f-b9a6-a151a9323249/PS12-Guideline-on-smoking-as-related-to-the-perioperative-period

12. Chow CK and Devereaux PJ. The optimal timing of smoking cessation before surgery: Comment on "Smoking cessation shortly before surgery and postoperative complications". Archives of Internal Medicine, 2011; 171(11):989-90. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21403012

13. Myers K, Hajek P, Hinds C, and McRobbie H. Stopping smoking shortly before surgery and postoperative complications: a systematic review and meta-analysis. Archives of Internal Medicine, 2011; 171(11):983-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21403009

14. Gronkjaer M, Eliasen M, Skov-Ettrup LS, Tolstrup JS, Christiansen AH, et al. Preoperative smoking status and postoperative complications: a systematic review and meta-analysis. Annals of Surgery, 2014; 259(1):52-71. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23799418

15. Araco A, Gravante G, Sorge R, Araco F, Delogu D, et al. Wound infections in aesthetic abdominoplasties: the role of smoking. Plastic and Reconstructive Surgery, 2008; 121(5):305e-10e. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18453943

16. Abbas SM and Hill AG. Smoking is a major risk factor for wound dehiscence after midline abdominal incision; case-control study. Australian and New Zealand Journal of Surgery, 2009; 79(4):247–50. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19432709

17. Pluvy I, Panouilleres M, Garrido I, Pauchot J, Saboye J, et al. Smoking and plastic surgery, part II. Clinical implications: a systematic review with meta-analysis. Annales de Chirurgie Plastique et Esthetique, 2015; 60(1):e15-49. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25447218

18. Araco F, Gravante G, Sorge R, Overton J, De Vita D, et al. The influence of BMI, smoking, and age on vaginal erosions after synthetic mesh repair of pelvic organ prolapses. A multicenter study. Acta Obstetricia et Gynecologica Scandinavica, 2009; 88(7):772-80. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19452293

19. Cundiff GW, Varner E, Visco AG, Zyczynski HM, Nager CW, et al. Risk factors for mesh/suture erosion following sacral colpopexy. American Journal of Obstetrics and Gynecology, 2008; 199(6):688 e1-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18976976

20. Sorensen LT. Wound healing and infection in surgery. The clinical impact of smoking and smoking cessation: a systematic review and meta-analysis. Archives of Surgery, 2012; 147(4):373-83. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22508785

21. Kokkinidis DG, Giannopoulos S, Haider M, Jordan T, Sarkar A, et al. Active smoking is associated with higher rates of incomplete wound healing after endovascular treatment of critical limb ischemia. Vascular Medicine, 2020; 25(5):427-35. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32460647

22. Sorensen LT. Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review. Annals of Surgery, 2012; 255(6):1069-79. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22566015

23. McRobert J. Smoking and its effects on the healing process of chronic wounds. British Journal of Community Nursing, 2013; Suppl(S18):S18, S20-3. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23682498

24. Leithead JA, Ferguson JW, and Hayes PC. Smoking-related morbidity and mortality following liver transplantation. Liver Transplantation, 2008; 14(8):1159-64. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18668649

25. Arora S, Aukrust P, Andreassen A, Simonsen S, Gude E, et al. The prognostic importance of modifiable risk factors after heart transplantation. American Heart Journal, 2009; 158(3):431-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19699867

26. Kubasiak JC, Landin M, Schimpke S, Poirier J, Myers JA, et al. The effect of tobacco use on outcomes of laparoscopic and open ventral hernia repairs: a review of the NSQIP dataset. Surgical Endoscopy, 2017; 31(6):2661-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27752819

27. Bayfield NGR, Pannekoek A, and Tian DH. Preoperative cigarette smoking and short-term morbidity and mortality after cardiac surgery: a meta-analysis. Heart Asia, 2018; 10(2):e011069. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30397415

28. Lalys F, Durrmann V, Dumenil A, Goksu C, Cardon A, et al. Systematic review and meta-analysis of preoperative risk factors of type II endoleaks after endovascular aneurysm repair. Annals of Vascular Surgery, 2017; 41:284-93. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27903482

29. Shahim B, Redfors B, Chen S, Morice MC, Gersh BJ, et al. Outcomes after left main coronary artery revascularization by percutaneous coronary intervention or coronary artery bypass grafting according to smoking status. American Journal of Cardiology, 2020; 127:16-24. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32360038

30. Kim TI, Zhang Y, Amin HP, and Ochoa Chaar CI. Presentation and outcomes of carotid endarterectomy in active smokers. Journal of Vascular Surgery, 2020; 72(5):1720-7 e1. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32249043

31. Teng S, Yi C, Krettek C, and Jagodzinski M. Smoking and risk of prosthesis-related complications after total hip arthroplasty: a meta-analysis of cohort studies. PLoS ONE, 2015; 10(4):e0125294. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25909602

32. Santiago-Torres J, Flanigan DC, Butler RB, and Bishop JY. The effect of smoking on rotator cuff and glenoid labrum surgery: a systematic review. American Journal of Sports Medicine, 2015; 43(3):745-51. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24859982

33. Bedard NA, DeMik DE, Owens JM, Glass NA, DeBerg J, et al. Tobacco use and risk of wound complications and periprosthetic joint infection: A systematic review and meta-analysis of primary total joint arthroplasty procedures. Journal of Arthroplasty, 2019; 34(2):385-96 e4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30385090

34. Cancienne JM, Brockmeier SF, and Werner BC. Tobacco use is associated with increased rates of infection and revision surgery after primary superior labrum anterior and posterior repair. Journal of Shoulder and Elbow Surgery, 2016; 25(11):1764-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27262413

35. Carender CN, DeMik DE, Bedard NA, Glass NA, and Brown TS. Increased risk of short-term complications in smokers undergoing primary unicompartmental knee arthroplasty. Journal of Knee Surgery, 2020. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32898899

36. Schwartz AM, Farley KX, Boden SH, Wilson JM, Daly CA, et al. The use of tobacco is a modifiable risk factor for poor outcomes and readmissions after shoulder arthroplasty. The Bone & Joint Journal, 2020; 102-B(11):1549-54. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33135438

37. Agrawal S, Ingrande J, Said ET, and Gabriel RA. The association of preoperative smoking with postoperative outcomes in patients undergoing total hip arthroplasty. Journal of Arthroplasty, 2021; 36(3):1029-34. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33616063

38. Best MJ, Aziz KT, Nayar SK, Patten IS, Bansal A, et al. Smoking is an independent risk factor for complications following open rotator cuff repair. Physician and Sportsmedicine, 2020; 48(4):469-72. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32266846

39. Kashanchi KI, Nazemi AK, Komatsu DE, and Wang ED. Smoking as a risk factor for complications following arthroscopic rotator cuff repair. JSES International, 2021; 5(1):83-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33554170

40. Bojan B, Perni S, and Prokopovich P. Systematic review and meta-analysis of tobacco use as a risk factor for prosthetic joint infection after total hip replacement. Arthroplasty today, 2020; 6(4):959-71. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33385034

41. Badiee RK, Chan AK, Rivera J, Molinaro A, Chou D, et al. Smoking is an independent risk factor for 90-day readmission and reoperation following posterior cervical decompression and fusion. Neurosurgery, 2021; 88(6):1088-94. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33575788

42. Smith EJ, Inkrott BP, Du JY, Ahn UM, and Ahn NU. Effect of nicotine dependence and smoking on revision diskectomy after single-level lumbar diskectomy. Orthopedics, 2020; 43(5):e438-e41. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32602915

43. Du JY, Weinberg DS, Moore TA, and Vallier HA. Smoking is associated with longer intensive care unit stays in spine trauma patients. Journal of Orthopaedic Trauma, 2020; 34(7):e250-e5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31972710

44. Beck EC, Gowd AK, White JC, Knio ZO, and O'Gara TJ. The effect of smoking on achieving meaningful clinical outcomes 1-year after lumbar tubular microdecompression: A matched-pair cohort analysis. Spine Journal, 2021. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33774211

45. Cho BH, Aziz KT, and Giladi AM. The impact of smoking on early postoperative complications in hand surgery. Journal of Hand Surgery (American Volume), 2021; 46(4):336 e1- e11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32868099

46. Galivanche AR, FitzPatrick S, Dussik C, Malpani R, Nduaguba A, et al. A matched comparison of postoperative complications between smokers and nonsmokers following open reduction internal fixation of distal radius fractures. Journal of Hand Surgery (American Volume), 2021; 46(1):1-9 e4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33390240

47. Connor M, Bonney PA, Lamorie-Foote K, Shkirkova K, Rangwala SD, et al. Tobacco use is associated with readmission within 90 days after craniotomy. Clinical Neurology and Neurosurgery, 2021; 200:106383. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33296843

48. Henriksen NA, Bisgaard T, Helgstrand F, and Danish Hernia D. Smoking and obesity are associated with increased readmission after elective repair of small primary ventral hernias: A nationwide database study. Surgery, 2020; 168(3):527-31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32460998

49. Novikov DA, Swensen SJ, Buza JA, 3rd, Gidumal RH, and Strauss EJ. The effect of smoking on ACL reconstruction: a systematic review. Physician and Sportsmedicine, 2016; 44(4):335-41. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27456300

50. Cancienne JM, Gwathmey FW, Miller MD, and Werner BC. Tobacco use is associated with increased complications after anterior cruciate ligament reconstruction. American Journal of Sports Medicine, 2016; 44(1):99-104. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26526974

51. McCarthy CM, Mehrara BJ, Riedel E, Davidge K, Hinson A, et al. Predicting complications following expander/implant breast reconstruction: an outcomes analysis based on preoperative clinical risk. Plastic and Reconstructive Surgery, 2008; 121(6):1886-92. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18520873

52. Padubidri AN, Yetman R, Browne E, Lucas A, Papay F, et al. Complications of postmastectomy breast reconstructions in smokers, ex-smokers, and nonsmokers. Plastic and Reconstructive Surgery, 2001; 107(2):342-9; discussion 50-1. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11214048

53. Bartsch RH, Weiss G, Kastenbauer T, Patocka K, Deutinger M, et al. Crucial aspects of smoking in wound healing after breast reduction surgery. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2007; 60(9):1045-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17662466

54. Bikhchandani J, Varma S, and Henderson H. Is it justified to refuse breast reduction to smokers? Journal of Plastic, Reconstructive and Aesthetic Surgery, 2007; 60(9):1050–4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17512812

55. Zhang MX, Chen CY, Fang QQ, Xu JH, Wang XF, et al. Risk factors for complications after reduction mammoplasty: A meta-analysis. PLoS ONE, 2016; 11(12):e0167746. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27936188

56. Hillam JS, Borsting EA, Chim JH, and Thaller SR. Smoking as a risk factor for breast reduction: An analysis of 13,503 cases. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2017; 70(6):734-40. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28237520

57. Anis KH, Weinrauch LA, and D'Elia JA. Effects of smoking on solid organ transplantation outcomes. American Journal of Medicine, 2019; 132(4):413-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30452885

58. Nogueira JM, Haririan A, Jacobs SC, Cooper M, and Weir MR. Cigarette smoking, kidney function, and mortality after live donor kidney transplant. American Journal of Kidney Diseases, 2010; 55(5):907-15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20176427

59. Arora S, Aukrust P, Andreassen A, Simonsen S, Gude E, et al. The prognostic importance of modifiable risk factors after heart transplantation. American Heart Journal, 2009; 158(3):431–6. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19699867

60. Tsao CI, Chen RJ, Chou NK, Ko WJ, Chi NH, et al. The influence of donor characteristics on survival after heart transplantation. Transplantation Proceedings, 2008; 40(8):2636-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18929825

61. Duerinckx N, Burkhalter H, Engberg SJ, Kirsch M, Klem ML, et al. Correlates and outcomes of posttransplant smoking in solid organ transplant recipients: A systematic literature review and meta-analysis. Transplantation, 2016; 100(11):2252-63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27479162

62. Hussain Z, Yu M, Wozniak A, Kim D, Krepostman N, et al. Impact of donor smoking history on post heart transplant outcomes: A propensity-matched analysis of ISHLT registry. Clinical Transplantation, 2021; 35(1):e14127. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33098160

63. Ohiomoba RO, Youmans QR, Akanyirige PW, Ezema AU, Anderson AS, et al. History of cigarette smoking and heart transplant outcomes. IJC Heart & Vasculature, 2020; 30:100599. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32775604

64. Bright RP. Denial of hepatic transplantation on the basis of smoking: is it ethical? Current Opinion in Organ Transplantation, 2010; 15(2):249-53. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20154621

65. Ehlers S. Ethical analysis and consideration of health behaviors in organ allocation: focus on tobacco use. Transplantation Reviews, 2008; 22(3):171–7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18631873

66. Sharkey K and Gillam L. Should patients with self-inflicted illness receive lower priority in access to healthcare resources? Mapping out the debate. Journal of Medical Ethics, 2010; 36(11):661-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20817816

67. Kauffman-Ortega C, Martinez-Delgado GH, Garza-Gangemi AM, Oropeza-Aguilar M, Gabilondo-Pliego B, et al. Short- and mid-term impact of tobacco smoking on donor renal function following living kidney donation at a tertiary referral hospital. Revista de Investigacion Clinica, 2021. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33845485

68. Li Y, Nieuwenhuis LM, Werner MJM, Voskuil MD, Gacesa R, et al. Donor tobacco smoking is associated with postoperative thrombosis after primary liver transplantation. Journal of Thrombosis and Haemostasis, 2020; 18(10):2590-600. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32614986

69. Sinha RJ, Singh V, and Sankhwar SN. Does tobacco consumption influence outcome of oral mucosa graft urethroplasty? Urology Journal, 2010; 7(1):45-50. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20209456

70. Kaylie DM, Bennett ML, Davis B, and Jackson CG. Effects of smoking on otologic surgery outcomes. Laryngoscope, 2009; 119(7):1384-90. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19418530

71. Sadr Azodi O, Lindstrom D, Adami J, Bellocco R, Linder S, et al. Impact of body mass index and tobacco smoking on outcome after open appendicectomy. British Journal of Surgery, 2008; 95(6):751-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18418861

72. Landin M, Kubasiak JC, Schimpke S, Poirier J, Myers JA, et al. The effect of tobacco use on outcomes of laparoscopic and open inguinal hernia repairs: a review of the NSQIP dataset. Surgical Endoscopy, 2017; 31(2):917-21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27351659

73. Haskins IN, Amdur R, and Vaziri K. The effect of smoking on bariatric surgical outcomes. Surgical Endoscopy, 2014; 28(11):3074-80. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24902816

74. Haskins IN, Nowacki AS, Khorgami Z, Schulz K, Heinberg LJ, et al. Should recent smoking be a contraindication for sleeve gastrectomy? Surgery for Obesity and Related Diseases, 2017; 13(7):1130-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28420587

75. Chow A, Neville A, and Kolozsvari N. Smoking in bariatric surgery: a systematic review. Surgical Endoscopy, 2021; 35(6):3047-66. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32524412

76. Napolitano MA, Rosenfeld ES, Chen SW, Sparks AD, Antevil JL, et al. Impact of timing of smoking cessation on 30-day outcomes in veterans undergoing lobectomy for cancer. Seminars in Thoracic and Cardiovascular Surgery, 2020. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33207278

77. Wong J, Lam DP, Abrishami A, Chan MT, and Chung F. Short-term preoperative smoking cessation and postoperative complications: a systematic review and meta-analysis. Canadian Journal of Anaesthesia, 2012; 59(3):268-79. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22187226

78. Thomsen T, Villebro N, and Moller AM. Interventions for preoperative smoking cessation. Cochrane Database of Systematic Reviews, 2014; 3(3):CD002294. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24671929

79. Benedetto U, Albanese A, Kattach H, Ruggiero D, De Robertis F, et al. Smoking cessation before coronary artery bypass grafting improves operative outcomes. Journal of Thoracic and Cardiovascular Surgery, 2014; 148(2):468-74. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24189314

80. Masoudkabir F, Yavari N, Pashang M, Sadeghian S, Jalali A, et al. Smoking cessation after surgery and midterm outcomes of surgical revascularization. Annals of Thoracic Surgery, 2020; 109(6):1874-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31706875

81. Schaffer SD, Yoon S, and Zadezensky I. A review of smoking cessation: potentially risky effects on prescribed medications. Journal of Clinical Nursing, 2009; 18(11):1533-40. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19490292

82. Benowitz NL. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction. New England Journal of Medicine, 1988; 319(20):1318-30. Available from: https://www.ncbi.nlm.nih.gov/pubmed/3054551

83. Kroon LA. Drug interactions with smoking. American Journal of Health-System Pharmacy, 2007; 64(18):1917-21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17823102

84. Anderson GD and Chan LN. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clinical Pharmacokinetics, 2016; 55(11):1353-68. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27106177

85. Sohn HS, Kim H, Song IS, Lim E, Kwon M, et al. Evidence supporting the need for considering the effects of smoking on drug disposition and effectiveness in medication practices: a systematic narrative review. International Journal of Clinical Pharmacology and Therapeutics, 2015; 53(8):621-34. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26104035

86. Zevin S and Benowitz NL. Drug interactions with tobacco smoking. An update. Clinical Pharmacokinetics, 1999; 36(6):425-38. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10427467

87. Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, Morarai T, Yodting T, et al. Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. Chest, 2011; 139(5):1130-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21540214

88. Perlik F. Impact of smoking on metabolic changes and effectiveness of drugs used for lung cancer. Central European Journal of Public Health, 2020; 28(1):53-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32228818

89. Sonnex K, Alleemudder H, and Knaggs R. Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review. BMJ Open, 2020; 10(4):e037509. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32300001

90. US Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease. A report of the US Surgeon General, Atlanta, Georgia: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2010. Available from: http://www.surgeongeneral.gov/library/tobaccosmoke/report/index.html.

91. Gagne JJ, Bykov K, Choudhry NK, Toomey TJ, Connolly JG, et al. Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. Bmj, 2013; 347(f5307):f5307. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24046285

92. Bossard M, Granger CB, Tanguay JF, Montalescot G, Faxon DP, et al. Double-dose versus standard-dose clopidogrel according to smoking status among patients with acute coronary syndromes undergoing percutaneous coronary intervention. Journal of the American Heart Association, 2017; 6(11):pii:e006577. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29101117

93. Gagne JJ, Bykov K, Choudhry NK, Toomey TJ, Connolly JG, et al. Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis and indirect comparison BMJ (Clinical Research Ed.), 2013; 347(f5307). Available from: https://europepmc.org/article/pmc/pmc3775704

94. Wagner E, McMahon L, Falkai P, Hasan A, and Siskind D. Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis. Acta Psychiatrica Scandinavica, 2020; 142(6):456-66. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32869278

95. Ahmad T, Barnes PJ, and Adcock IM. Overcoming steroid insensitivity in smoking asthmatics. Current Opinion in Investigational Drugs, 2008; 9(5):470-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18465656

96. Braganza G, Chaudhuri R, and Thomson NC. Treating patients with respiratory disease who smoke. Therapeutic Advances in Respiratory Disease, 2008; 2(2):95-107. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19124362

97. van Dijk WD, Heijdra Y, Scheepers PT, Lenders JW, van Weel C, et al. Interaction in COPD experiment (ICE): a hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease. Medical Hypotheses, 2010; 74(2):277-80. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19800175

98. Frey P, Waters DD, DeMicco DA, Breazna A, Samuels L, et al. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials). American Journal of Cardiology, 2011; 107(2):145-50. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21129718

99. Ursoniu S, Mikhailidis DP, Serban MC, Penson P, Toth PP, et al. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2017; 122:105-17. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28602797

100. Lindsay GM, Tolmie EP, Martin WM, Hutton IM, and Belcher PR. Smoking after coronary artery bypass: high three-year mortality. Thoracic and Cardiovascular Surgeon, 2009; 57(3):135-40. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19330749

101. Conard MW, Haddock CK, Poston WS, Spertus JA, and Cardiovascular Outcomes Research C. The impact of smoking status on the health status of heart failure patients. Congestive Heart Failure, 2009; 15(2):82-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19379454

102. Ma WQ, Wang Y, Sun XJ, Han XQ, Zhu Y, et al. Impact of smoking on all-cause mortality and cardiovascular events in patients after coronary revascularization with a percutaneous coronary intervention or coronary artery bypass graft: a systematic review and meta-analysis. Coronary Artery Disease, 2019; 30(5):367-76. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30629001

103. US Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014. Available from: https://www.ncbi.nlm.nih.gov/books/NBK179276/pdf/Bookshelf_NBK179276.pdf.

104. Togawa K, Bhatti L, Tursan d’Espaignet E, Leon Roux M, Ullrich A, et al. WHO tobacco knowledge summaries: tobacco and cancer treatment outcomes. Geneva: World Health Organization, 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/273077/WHO-NMH-PND-TKS-18.1-eng.pdf?ua=1.

105. Ordonez-Mena JM, Walter V, Schottker B, Jenab M, O'Doherty MG, et al. Impact of pre-diagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts wtihin the CHANCES consortium. . Annals of Oncology, 2018; 29:472-83. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29244072

106. Sutton E, Miyagaki H, Bellini G, Shantha Kumara HM, Yan X, et al. Risk factors for superficial surgical site infection after elective rectal cancer resection: a multivariate analysis of 8880 patients from the American College of Surgeons National Surgical Quality Improvement Program database. Journal of Surgical Research, 2017; 207:205-14. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27979478

107. Bastian LA. Pain and smoking among cancer patients: the relationship is complex but the clinical implication is clear. Pain, 2011; 152(1):10-1. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21168757

108. Daniel M, Keefe F, Lyna P, Peterson B, Garst J, et al. Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels. Journal of Pain, 2009; 10(3):323–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684817/

109. Logan HL, Fillingim RB, Bartoshuk LM, Sandow P, Tomar SL, et al. Smoking status and pain level among head and neck cancer patients. Journal of Pain, 2010; 11(6):528-34. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20015696

110. Cacciamani GE, Ghodoussipour S, Mari A, Gill KS, Desai M, et al. Association between smoking exposure, neoadjuvant chemotherapy response and survival outcomes following radical cystectomy: systematic review and meta-analysis. Journal of Urology, 2020; 204(4):649-60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32105187

111. Wong G, Lam E, Karam I, Yee C, Drost L, et al. The impact of smoking on adjuvant breast cancer radiation treatment: A systematic review. Cancer Treatment and Research Communications, 2020; 24:100185. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32593846

112. Scheidl S, Avian A, Flick H, Gaal S, Greinix H, et al. Impact of smoking behavior on survival following allogeneic hematopoietic stem cell transplantation - smoking cessation matters. Nicotine and Tobacco Research, 2021. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33837775

113. Wallis CJD, Satkunasivam R, Butaney M, Khan UA, Goldberg HA, et al. Association between smoking and survival benefit of immunotherapy in advanced malignancies: A systematic review and meta-analysis. American Journal of Clinical Oncology, 2019; 42(9):711-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31335350

114. Cortellini A, De Giglio A, Cannita K, Cortinovis DL, Cornelissen R, et al. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. Thoracic Cancer, 2021; 12(6):880-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33527756

115. Fukuokaya W, Kimura T, Yanagisawa T, Kimura S, Tsuzuki S, et al. Impact of dose-effect in smoking on the effectiveness of pembrolizumab in patients with metastatic urothelial carcinoma. Targeted Oncology, 2021; 16(2):189-96. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33400096

116. Mo J, Hu X, Gu L, Chen B, Khadaroo PA, et al. Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. World Journal of Surgical Oncology, 2020; 18(1):15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31959178

117. Nie RC, Duan JL, Liang Y, Chen XJ, Chen YM, et al. Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. Immunotherapy, 2020; 12(18):1313-24. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33012209

118. Warren GW, Sobus S, and Gritz ER. The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncology, 2014; 15(12):e568-80. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25439699

119. US Department of Health and Human Services. Smoking cessation. A report of the Surgeon General. Atlanta, GA U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Centre for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health  2020. Available from: https://www.cdc.gov/tobacco/data_statistics/sgr/2020-smoking-cessation/.

120. Fukui M, Suzuki K, Matsunaga T, Oh S, and Takamochi K. Importance of smoking cessation on surgical outcome in primary lung cancer. Annals of Thoracic Surgery, 2019; 107(4):1005-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30610851

121. Budani MC and Tiboni GM. Ovotoxicity of cigarette smoke: A systematic review of the literature. Reproductive Toxicology, 2017; 72:164-81. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28684319

122. Budani MC, Fensore S, Di Marzio M, and Tiboni GM. Cigarette smoking impairs clinical outcomes of assisted reproductive technologies: A meta-analysis of the literature. Reproductive Toxicology, 2018; 80:49-59. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29906539

123. Zhang RP, Zhao WZ, Chai BB, Wang QY, Yu CH, et al. The effects of maternal cigarette smoking on pregnancy outcomes using assisted reproduction technologies: An updated meta-analysis. Journal of Gynecology Obstetrics and Human Reproduction, 2018; 47(9):461-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30142473

124. Waylen A, Metwally M, Jones G, Wilkinson A, and Ledger W. Effects of cigarette smoking upon clinical outcomes of assisted reproduction: a meta-analysis. Human Reproduction Update, 2009; 15(1):31–44. Available from: http://humupd.oxfordjournals.org/content/15/1/31.long

125. Firns S, Cruzat VF, Keane KN, Joesbury KA, Lee AH, et al. The effect of cigarette smoking, alcohol consumption and fruit and vegetable consumption on IVF outcomes: a review and presentation of original data. Reproductive Biology and Endocrinology, 2015; 13:134. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26669322

126. Klonoff-Cohen H, Natarajan L, Marrs R, and Yee B. Effects of female and male smoking on success rates of IVF and gamete intra-Fallopian transfer. Human Reproduction, 2001; 16(7):1382-90. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11425817

127. Eshre Task Force on Ethics Law, Dondorp W, de Wert G, Pennings G, Shenfield F, et al. Lifestyle-related factors and access to medically assisted reproduction. Human Reproduction, 2010; 25(3):578-83. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20085914

128. Barbieri RL. The initial fertility consultation: recommendations concerning cigarette smoking, body mass index, and alcohol and caffeine consumption. American Journal of Obstetrics and Gynecology, 2001; 185(5):1168-73. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11717652

129. Petanovska Kostova E. The interaction of female age and active male smoking has negative influence on success rates of the in vitro fertilization treatments. Balkan Journal of Medical Genetics, 2020; 23(1):57-62. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32953410

130. Tong VT, Kissin DM, Bernson D, Copeland G, Boulet SL, et al. Maternal smoking among women with and without use of assisted reproductive technologies. Journal of Women's Health, 2016; 25(10):1066-72. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27243366

131. Keeling D. Combined oral contraceptives and the risk of myocardial infarction. Annals of Medicine, 2003; 35(6):413-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/14572165

132. British Medical Association Board of Science and Education and Tobacco Control Resource Centre, Smoking and reproductive life. The impact of smoking on sexual, reproductive and child health. London: British Medical Association; 2004. Available from: https://www.rauchfrei-info.de/fileadmin/main/data/Dokumente/Smoking_ReproductiveLife.pdf.

133. US Department of Health and Human Services, Women and smoking. A report of the US Surgeon General. Atlanta, Georgia: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health,; 2001. Available from: https://www.cdc.gov/tobacco/data_statistics/sgr/2001/index.htm.

134. Liebman SE, Lamontagne SP, Huang LS, Messing S, and Bushinsky DA. Smoking in dialysis patients: a systematic review and meta-analysis of mortality and cardiovascular morbidity. American Journal of Kidney Diseases, 2011; 58(2):257-65. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21664017

135. Klifto KM, Shetty PN, Slavin BR, Gurno CF, Seal SM, et al. Impact of nicotine/smoking, alcohol, and illicit substance use on outcomes and complications of burn patients requiring hospital admission: systematic review and meta-analysis. Burns, 2019; S0305-4179(19):30286-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31818513